Bank of America Corporation (NYSE: BAC) has crossed above the 5% voting rights threshold in Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT), according to a transparency notification filed on May 20, 2026.

The threshold crossing occurred on May 13, 2026, following Bank of America's acquisition of voting rights and equivalent financial instruments in the biotherapeutics company. As of May 20, 2026, Bank of America and its affiliates owned 623,434 voting rights and 5,502,802 equivalent financial instruments, representing 9.30% of Lakefront's 65,897,071 outstanding shares.

The notification shows Bank of America holds 0.95% in direct voting rights and 8.35% through equivalent financial instruments. The equivalent financial instruments include various derivatives such as swaps, call options, and rights of use held by Bank of America subsidiaries including BofA Securities Inc., Merrill Lynch International, and Bank of America National Association.

The largest component of the equivalent financial instruments position consists of 5,068,385 voting rights through BofA Securities Inc.'s "Right to Use" instruments, representing 7.69% of outstanding shares. Additional exposure comes through swap agreements with expiration dates ranging from June 2026 to October 2027.

Belgian transparency legislation requires disclosure when crossing certain ownership thresholds in publicly traded companies. The notification indicates the reason for the disclosure was the "acquisition or disposal of financial instruments that are treated as voting securities."

Lakefront Biotherapeutics trades on both the Euronext exchange and NASDAQ under the ticker LKFT.